Skip to main content

Table 1 Baseline AGEs and sRAGE levels

From: Relationship between Advanced Glycation End Products and Plaque Progression in Patients with Acute Coronary Syndrome: The JAPAN-ACS Sub-study

Background   N = 208 AGEs* (U/mL) P-value sRAGE* (pg/mL) P-value
Statin Atorvastatin 98 8.56 ± 2.35 0.99 736 (494–1099) 0.6
Pitavastatin 110 8.56 ± 2.04 681 (492–1016)
Gender Women 42 8.00 ± 2.22 0.06 704 (413–1104) 0.8
Men 166 8.71 ± 2.17 692 (494–1004)
Diabetes mellitus No 146 8.44 ± 2.14 0.2 692 (481–1015) 0.2
  Yes 62 8.86 ± 2.28   755 (552–1096)  
Hypertension No 81 8.46 ± 2.22 0.6 684 (489–1022) 0.8
  Yes 127 8.63 ± 2.18   718 (494–1095)  
Smoking No 112 8.25 ± 2.14 0.028 692 (541–1050) 0.5
Yes 96 8.92 ± 2.20 707 (453–1037)
ST elevation No 74 8.63 ± 2.10 0.7 720 (537–949) 0.8
Yes 134 8.53 ± 2.24 683 (472–1080)
  1. *Data of AGEs were expressed as mean ± SD and those of sRAGE were median (interquartile range). AGEs, Advanced glycation end products; sRAGE, serum Receptor of AGE.